NLS wntresearch

WntResearch announces that, after reviewing available research results and further consultations with experts in oncology and surgery, the company has revised the design of the planned Phase 2 clinical study of its drug candidate Foxy-5. The revised study design will delay the study initiation compared to the previous estimate (year-end 2017/18). However, the impact on […]

WntResearch has announces that the Danish regulatory authorities and the ethics committee have approved the protocol for the Phase 1b study with Foxy-5. The study will start immediately. With the Danish regulatory authorities and the ethics committee having approved the protocol for the previously announced Phase 1b study with Foxy-5, two Danish research centres (Rigshospitalet in Copenhagen […]

The company has submitted an application to the Danish Health Authorities regarding permission to start the Foxy-5 clinical phase 1b study. “This is a very important milestone for WntResearch. I feel confident that the phase 1b study will provide us with the information needed to optimize conditions for the pivotal clinical phase 2 study. The […]